- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05589454
Intracranial Hemorrhage Risk of Intensive Statin in Acute Ischemic Stroke With Cerebral Microbleeds
Intracranial Hemorrhage Risk of Intensive Statin Therapy in Patients With Acute Ischemic Stroke Combined With Cerebral Microbleeds
This study is the first and largest secondary prevention trial about lipid-lowering therapy for acute ischemic stroke patients at high-risk of intracranial hemorrhage.
The primary hypothesis of this study is: excessive reduction in serum lipid levels by intensive statin therapy in acute ischemic stroke patients with cerebral microbleeds can increase the risk of intracranial hemorrhage.
This study will shed light on new clinical decisions regarding the long-term serum lipid management in these patients with dilemma in clinical practice.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cerebral microbleeds are an important subtype of cerebral small vessel diseases that have been established in approximately one third of patients with ischemic stroke and are associated with the risk of recurrent ischemic stroke, symptomatic intracranial hemorrhage, and all-cause death. In patients with ischemic stroke or transient ischemic attack, the relative and absolute risks of intracranial hemorrhage increase more rapidly than the risk of ischemic stroke with the increase of cerebral microbleeds burden, but the absolute incidence of ischemic stroke is still higher than that of cerebral hemorrhage.
It has been generally accepted that statins can effectively prevent recurrent ischemic stroke by reducing serum lipid levels. However, both low serum lipid levels and high dose of statins are clear risk factors for intracerebral hemorrhage, and the reduction of major serum lipid levels may increase the risk of cerebral microbleeds. Of note, the risk of statin mediated hemorrhage appears to depend on the degree of lipid reduction rather than statin use per se. These observations raise concerns about the safety of lipid-lowering therapy, especially intensive lipid-lowering therapy, in patients with acute ischemic stroke and cerebral microbleeds who are at high risk for future intracranial hemorrhage. It is still not clear that how to carry on the proper management of serum lipid levels in this particular population to reduce the recurrence of ischemic events as well as hemorrhagic events, for there is still a lack of clinical studies to explore the risk and benefit of different doses of statins to achieve different degrees of lipid regulation.
So, if it is proved that excessive reduction in serum lipid levels by intensive statin therapy in acute ischemic stroke patients with cerebral microbleeds can increase the risk of future intracranial hemorrhage, we will inform new clinical decisions regarding the long-term lipid management in these patients with dilemma in clinical practice.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Jialing Zhao, MD
- Phone Number: +8618113137196
- Email: jailynyy@163.com
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 404599
- Yunyang County People's Hospital
-
-
Sichuan
-
Chengdu, Sichuan, China, 610072
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
-
Chengdu, Sichuan, China, 610017
- Chengdu Eighth People's Hospital
-
Ya'an, Sichuan, China, 625000
- Ya 'an People's Hospital
-
Zigong, Sichuan, China, 643021
- Zigong Third People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a non-cardioembolic ischemic stroke within 14 days prior to entry to the study
- Adults between the ages of 18 and 85
- Patients with cerebral microbleeds on baseline SWI imaging
- Patients or their legal representatives volunteer to participate and sign written informed consent
Exclusion Criteria:
- Patients with severe acute ischemic stroke (NIHSS score ≥21)
- Patients with coma (GCS score < 8)
- Patients with previous moderate to severe dependence (mRS score 3-5)
- Patients with any contraindications to CT and MRI (such as metal implants, claustrophobia, etc.)
- Patients who are allergic to atorvastatin or excipients
- Patients with intracranial hemorrhagic diseases confirmed by CT or MRI, such as cerebral hemorrhage, epidural hematoma, subdural hematoma, ventricular hemorrhage, subarachnoid hemorrhage, traumatic cerebral hemorrhage or hemorrhagic conversion of infarcts, etc
- Patients within 6 months after hemorrhagic stroke
- Patients with hemorrhagic tendency, such as abnormal coagulation function, Henoch-Schonlein purpura, platelet count less than 100×109/L or abnormal platelet function, etc
- Patients who are ready to undergo or have undergone intravenous thrombolysis after the onset of the disease or who require urgent or recent (within 90 days) endovascular treatment;
- Patients with severe hypertension (systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) that has not been controlled by treatment
- Patients with hypoglycemia (< 2.7 mmol/L) or hyperglycemia (>22.2 mmol/L)
- Patients with previous cerebral arteritis, brain tumor, cerebral parasitic disease, cerebral arteriovenous malformation, cerebral cavernous hemangioma, cerebral aneurysm, severe craniocerebral injury, or intracranial infection
- Patients with previous severe valvular heart disease, atrial fibrillation, acute myocardial infarction or interventional therapy in the past 6 months, heart failure (patients classified as class III-IV according to the New York Heart Association [NYHA]) or patients with indications for pacemaker placement but without pacemaker installation or other malignant arrhythmias
- Patients contraindicate to antiplatelet therapy;
- Patients who must use other types of statins or other types of lipid-lowering drugs such as ezetimibe
- Patients with severe mental disorders or dementia that are unable or unwilling to cooperate
- Patients with active liver disease or unexplained 2 or more abnormal liver function tests (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] ≥ 3.0× upper limit of normal [ULN])
- Patients with myositis, myopathy, rhabdomyolysis, or 2 or more episodes of unexplained serum creatine kinase[CK] elevation ([CK]≥5.0×ULN)
- Patients with other serious systemic or organic diseases that investigators believe will not allow evaluation of efficacy or are unlikely to complete the expected course of treatment and follow-up (e.g., malignancy, life expectancy < 3 years, etc.)
- Women who are pregnant, breastfeeding or planning to become pregnant and who do not want to use contraception
- Patients who participated in or are participating in other clinical trials during the 3 months prior to the study
- Patients who are deemed ineligible for clinical trial participation by the investigator
- Patients or their legal representatives do not consent to participate in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: High-dose atorvastatin
atorvastatin calcium tablets 80 mg, quaque nocte, continue to the end of the study
|
Atorvastatin calcium tablets 4 pills (80 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
Other Names:
|
ACTIVE_COMPARATOR: Low-dose atorvastatin
atorvastatin calcium tablets 20 mg, quaque nocte, continue to the end of the study
|
Atorvastatin calcium tablets 1 pill (20 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of hemorrhagic strokes
Time Frame: From date of randomization until the date of the first occurrence of hemorrhagic stroke, assessed up to 36 months
|
From date of randomization until the date of the first occurrence of hemorrhagic stroke, assessed up to 36 months
|
|
Changes in degree of cerebral microbleeds
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
The degree is divided into: mild (1-2), moderate (3-10), severe (more than 10), calculate and compare the proportions of different degrees at baseline and the end of the study
|
From date of randomization until the end of the study, assessed up to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Incidence of recurrent ischemic stroke and transient ischemic attack
Time Frame: From date of randomization until the date of the first recurrent of ischemic stroke or the first occurrence of transient ischemic attack, assessed up to 36 months
|
From date of randomization until the date of the first recurrent of ischemic stroke or the first occurrence of transient ischemic attack, assessed up to 36 months
|
|
The Incidence of myocardial infarction
Time Frame: From date of randomization until the date of the first occurrence of myocardial infarction, assessed up to 36 months
|
From date of randomization until the date of the first occurrence of myocardial infarction, assessed up to 36 months
|
|
The Incidence of cardiovascular death
Time Frame: From date of randomization until the date of cardiovascular death, assessed up to 36 months
|
From date of randomization until the date of cardiovascular death, assessed up to 36 months
|
|
The mean of serum triglycerides (TG) levels
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
Calculate the mean of serum TG levels for 3 years with at least 3 measurements
|
From date of randomization until the end of the study, assessed up to 36 months
|
The mean of serum total cholesterol (TC) levels
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
Calculate the mean of serum TC levels for 3 years with at least 3 measurements
|
From date of randomization until the end of the study, assessed up to 36 months
|
The mean of serum low-density lipoprotein cholesterol (LDL-C) levels
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
Calculate the mean of serum LDL-C levels for 3 years with at least 3 measurements
|
From date of randomization until the end of the study, assessed up to 36 months
|
The mean of serum high-density lipoprotein cholesterol (HDL-C) levels
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
Calculate the mean of serum HDL-C levels for 3 years with at least 3 measurements
|
From date of randomization until the end of the study, assessed up to 36 months
|
The variability of serum triglycerides (TG) levels
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
Calculate the variability of serum TG levels for 3 years with at least 3 measurements
|
From date of randomization until the end of the study, assessed up to 36 months
|
The variability of serum total cholesterol (TC) levels
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
Calculate the variability of serum TC levels for 3 years with at least 3 measurements
|
From date of randomization until the end of the study, assessed up to 36 months
|
The variability of serum low-density lipoprotein cholesterol (LDL-C) levels
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
Calculate the variability of serum LDL-C levels for 3 years with at least 3 measurements
|
From date of randomization until the end of the study, assessed up to 36 months
|
The variability of serum high-density lipoprotein cholesterol (HDL-C) levels
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
Calculate the variability of serum HDL-C levels for 3 years with at least 3 measurements
|
From date of randomization until the end of the study, assessed up to 36 months
|
The proportions of different degrees of CMBs at the end of the study
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
Calculate the proportions of different degrees of CMBs (mild, moderate and severe) at the end of the study
|
From date of randomization until the end of the study, assessed up to 36 months
|
The correlation between the mean of serum triglycerides (TG) levels and the proportions of different degrees of CMBs
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
From date of randomization until the end of the study, assessed up to 36 months
|
|
The correlation between the mean of serum total cholesterol (TC) levels and the proportions of different degrees of CMBs
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
From date of randomization until the end of the study, assessed up to 36 months
|
|
The correlation between the mean of serum low-density lipoprotein cholesterol (LDL-C) levels and the proportions of different degrees of CMBs
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
From date of randomization until the end of the study, assessed up to 36 months
|
|
The correlation between the mean of serum high-density lipoprotein cholesterol (HDL-C) levels and the proportions of different degrees of CMBs
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
From date of randomization until the end of the study, assessed up to 36 months
|
|
The correlation between the variability of serum triglycerides (TG) levels and the proportions of different degrees of CMBs
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
From date of randomization until the end of the study, assessed up to 36 months
|
|
The correlation between the variability of serum total cholesterol (TC) levels and the proportions of different degrees of CMBs
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
From date of randomization until the end of the study, assessed up to 36 months
|
|
The correlation between the variability of serum low-density lipoprotein cholesterol (LDL-C) levels and the proportions of different degrees of CMBs
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
From date of randomization until the end of the study, assessed up to 36 months
|
|
The correlation between the variability of serum high-density lipoprotein cholesterol (HDL-C) levels and the proportions of different degrees of CMBs
Time Frame: From date of randomization until the end of the study, assessed up to 36 months
|
From date of randomization until the end of the study, assessed up to 36 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jialing Zhao, MD, Departement of Neurology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
- Study Director: Yang Xiang, MD, Departement of Neurology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Necrosis
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Brain Ischemia
- Infarction
- Brain Infarction
- Stroke
- Ischemic Stroke
- Ischemia
- Hemorrhage
- Cerebral Infarction
- Intracranial Hemorrhages
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Atorvastatin
- Calcium
- Calcium, Dietary
Other Study ID Numbers
- zjl8803302022NSCSC1374
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Ischemic Stroke
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)CompletedAcute Ischemic Stroke (AIS)United States
-
Beijing Tiantan HospitalRecruitingIschemic Stroke, AcuteChina
-
Shanghai Yueyang Integrated Medicine HospitalRecruitingIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalCompletedIschemic Stroke, AcuteChina
-
Anaconda Biomed S.L.Not yet recruitingAcute Ischemic Stroke From Large Vessel Occlusion
-
Centre Hospitalier Sud FrancilienCompletedAcute Ischemic Stroke Due to Medium-vessel-occlusionFrance
Clinical Trials on Atorvastatin Calcium tablets 80mg
-
Dong-A ST Co., Ltd.Unknown
-
Organon and CoCompleted
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeActive, not recruitingCardiovascular Diseases | AtherosclerosisUnited Kingdom
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
Daiichi Sankyo, Inc.CompletedHypercholesterolemiaUnited States
-
Peking Union Medical College HospitalRecruiting
-
Zhongda HospitalNot yet recruitingAcute Ischemic Stroke | Mechanical ThrombectomyChina